Kivexa

RSS

abacavir / lamivudine

Authorised
This medicine is authorised for use in the European Union.

Overview

Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).

Kivexa contains two active substances, abacavir and lamivudine.

This EPAR was last updated on 07/01/2022

Authorisation details

Product details
Name
Kivexa
Agency product number
EMEA/H/C/000581
Active substance
  • abacavir
  • lamivudine
International non-proprietary name (INN) or common name
  • abacavir
  • lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR02
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Revision
35
Date of issue of marketing authorisation valid throughout the European Union
16/12/2004
Contact address

Van Asch van Wijckstraat 55H
3811 LP Amersfoort
The Netherlands

Product information

16/12/2021 Kivexa - EMEA/H/C/000581 - WS/2163

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Antivirals for treatment of HIV infections, combinations
  • Antivirals for systemic use

Therapeutic indication

Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.

Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Assessment history

How useful was this page?

Add your rating